Xenograft are the cells of one species transplanted to another species.
The goal of cancer therapy is to destroy the tumor or stop it from growing and spreading to other parts of the body.
Failure of hormone deprivation therapy, which is used to slow prostate cancer in patients, leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options.
Genetic mutations can increase a person's cancer risk, but other gene "enhancer" elements may also be responsible for disease progression, according to new research out of Case Western Reserve University School of Medicine.
Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy.
In a paper published today in Cancer Research, researchers: 1) identify a biomarker enzyme associated with aggressive glioma brain tumors, 2) reveal the regulatory mechanism for that enzyme, and 3) demonstrate potent efficacy, using a mouse model of glioma, for a small molecule inhibitor they have developed.
Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers.
Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease.
A team of Russian scientists from Moscow Institute of Physics and Technology, the N. D. Zelinsky Institute of Organic Chemistry, the Institute of Developmental Biology, and the Institute of Cell Biophysics proposed an efficient approach to a novel agents with anticancer activity.
A recent study led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, in collaboration with the Univerity of Maryland School of Pharmacy and StemSynergy Therapeutics, Inc., has identified a small-molecule inhibitor of the Notch pathway, paving the way for a potential new class of personalized cancer medicines.
A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents.
Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors.
In around 2004, there was a Phillips paper that discussed a new imaging technique called MPI. At that time, I had an eager, promising graduate student named Matt Ferguson who wanted a project, so I asked him to take a look.
Mangos contain numerous compounds that have been shown to exhibit antioxidant properties. These compounds include vitamin C and beta carotene, as well as several polyphenolic compounds including gallic acid and their larger polymers gallotannins,that have been linked to anti-cancer and anti-inflammatory activities in previous in vitro and in vivo studies.
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.
Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.
A diabetes drug that showed promise in previous studies as an anti-cancer treatment failed to show any benefit in a UNC Lineberger Comprehensive Cancer Center-led study that used pancreatic cancer tissue samples to test sensitivity to the drug.
Melanoma patients who receive treatment with targeted therapies experience an initial response that feels like a cure, but that early excitement is quickly dampened when patients relapse as their cancers find alternative pathways in our cells to grow and spread. With melanoma so good at escaping targeted treatments, there's a dire need to halt these cancers in their tracks to prolong good responses and promote longer, healthier lives.
Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.
The first clinically-relevant mouse model of human breast cancer to successfully express functional estrogen receptor positive (ER+) adenocarcinomas has been developed by researchers at Lawrence Berkeley National Laboratory.